Panels and models for accurate prediction of tumor mutation burden in tumor samples

Immune checkpoint blockade (ICB) is becoming standard-of-care in many types of human malignancies, but patient selection is still imperfect. Tumor mutation burden (TMB) is being evaluated as a biomarker for ICB in clinical trials, but most of the sequencing panels used to estimate it are inadequatel...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Pérez, Elizabeth, Molina-Vila, Miguel Angel, Marino-Buslje, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044185/
https://www.ncbi.nlm.nih.gov/pubmed/33850256
http://dx.doi.org/10.1038/s41698-021-00169-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044185/
https://www.ncbi.nlm.nih.gov/pubmed/33850256
http://dx.doi.org/10.1038/s41698-021-00169-0

Ejemplares similares